bevacizumab,panitumumab
amgen,roche,takeda
['bevacizumab', 'panitumumab', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'rectal', 'paradigm', 'colorectal', 'beva', 'amgenoncology', 'amgen']
dr. yoshino presents results from phase 3 paradigm tria: panitumumab plus mfolfox6 versus bevacizumab plus mfolfox6 as first-line treatment in patients with ras wild-type metastatic colorectal cancer #asco22 #crc #colorectalcancer hall b1 1:05pm
Creating Aha! Moments In Healthcare
IDEOlogy Health is leading the change in how healthcare professionals connect and stay up-to-date on the latest advancements